Elanco Animal Health (ELAN) director reports 10,314-share deferred stock grant on Form 4

Rhea-AI Filing Summary

Elanco Animal Health Inc. director equity grant reported

A director of Elanco Animal Health Inc. reported receiving an annual equity award on 11/28/2025. The filing shows an award of 10,314 shares of common stock, recorded at a price of $0 as a grant of deferred stock units to a non-employee member of the Board of Directors. Following this grant, the director beneficially owns 88,714 shares of Elanco common stock in direct ownership. This is a routine Form 4 disclosure of director compensation in equity rather than a cash transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scots-Knight Denise

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/28/2025		A		10,314	A	$0(1)	88,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Denise K. Scots-Knight	12/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elanco Animal Health Inc (ELAN) report?

The filing reports that a director of Elanco Animal Health Inc. received an equity grant on 11/28/2025. The director was awarded 10,314 shares of common stock in the form of deferred stock units as an annual equity award for serving on the Board of Directors.

How many ELAN shares were acquired in this Form 4 filing?

The director acquired 10,314 shares of Elanco Animal Health Inc. common stock. These were granted as deferred stock units and are recorded in the filing as an acquisition at a price of $0, reflecting that they are part of equity compensation rather than an open-market purchase.

What is the director’s total beneficial ownership of Elanco (ELAN) shares after the transaction?

After the reported equity grant, the director beneficially owns 88,714 shares of Elanco common stock. The ownership is listed as Direct (D), indicating the shares are held directly in the director’s name rather than through an intermediary entity.

What is the nature of the equity award reported for the Elanco director?

The equity award is described as a grant of deferred stock units made as an annual equity award to each non-employee member of Elanco’s Board of Directors. This means the director is compensated with stock-based units tied to Elanco common shares instead of cash.

Does this Elanco (ELAN) Form 4 involve a Rule 10b5-1 trading plan?

The form includes a checkbox to indicate whether a transaction was made under a Rule 10b5-1(c) trading plan, which can provide an affirmative defense for insider trading claims. The excerpt does not show that box marked as part of the transaction details provided.

Who signed the Elanco Animal Health Inc Form 4 and in what capacity?

The Form 4 was signed by /s/ Amy C. Seidel acting as Attorney-in-Fact for Denise K. Scots-Knight. This indicates Ms. Seidel signed on behalf of the reporting person under a power of attorney arrangement.